GlassScriptPhysician profile
Ashraf G Mikhail
NPI 1083690515
$3,748.85
in general payments reported to CMS, 2019-2025
22 companies · $545 in 2025
The $545 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489 · 2020: $315 · 2021: $40.82 · 2022: $730 · 2023: $838 · 2024: $792 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,174.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $720.20 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $432.31 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $424.82 | 2019-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Allergan, INC. | $398.02 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $345.76 | 2021-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $290.83 | 2019-2025 | Spravato, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $243.72 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Axsome Therapeutics, INC. | $144.64 | 2022-2025 | Auvelity |
| Alkermes, INC. | $141.12 | 2019-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $110.03 | 2019-2024 | Rexulti |
| Almatica Pharma LLC | $74.90 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Vanda Pharmaceuticals INC. | $73.67 | 2019-2025 | Hetlioz, Fanapt |
| Corium, LLC | $69.35 | 2023-2024 | Azstarys |
| Merck Sharp & Dohme LLC | $64.27 | 2022-2023 | Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $54.94 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $54.30 | 2019-2022 | |
| Tris Pharma INC | $26.01 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $22.10 | 2019 | |
| Luye Pharma (USA) LTD. | $16.24 | 2025 | Erzofri Extended-Release |
| E.R. Squibb & Sons, L.L.C. | $15.35 | 2025 | Cobenfy |
| Neos Therapeutics, LP | $14.10 | 2019 | |
| Ironshore Pharmaceuticals INC. | $12.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashraf Mikhail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.